Crestone, Inc.
Boulder, CO Doing business as Crestone Inc.
- UEI
- EDSLAP2J1BL8
- CAGE
- 5RDJ6
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 6075 Longbow Dr #130, Boulder, CO 80301, USA
- Website
- crestonepharma.com
- Founded
- 2009
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Synthesis and testing laboratory services for research | Veterans Integrated Service Network 19 | $98,948 | |
| Synthesis and testing of novel antibiotic chemical compounds for rocky mountain regional VA medical center research… | Veterans Integrated Service Network 19 | $102,140 | |
| A novel small molecule therapeutic for acute graft versus host disease - abstract allogeneic hematopoietic cell… | National Institute of Allergy and Infectious Diseases | $288,117 | |
| To advance a promising, small-molecule compound CRS0540 to IND filing and through phase i clinical studies. | National Institute of Allergy and Infectious Diseases | $22,028,937 | |
| Preclinical evaluation of CRS3123 for the treatment of helicobacter pylori infections | National Institute of Allergy and Infectious Diseases | $143,893 |
About Crestone, Inc.
Crestone, Inc. is a for-profit biotechnology company based in Boulder, Colorado, specializing in developing novel therapeutic treatments for antibiotic-resistant bacterial infections. Registered in SAM.gov since October 2009, the company has established itself as a key research partner for federal agencies, particularly in the medical and infectious disease research domains. The company focuses on synthesizing and testing laboratory services, with a strong emphasis on developing innovative pharmaceutical compounds targeting challenging medical conditions.
Through federal contract awards, Crestone, Inc. has consistently worked with the Department of Veterans Affairs' Veterans Integrated Service Network 19 and the National Institute of Allergy and Infectious Diseases (NIAID), securing multiple contracts for advanced research initiatives. The company has been awarded several purchase orders and definitive contracts, including a significant $23,548,569 cost-plus-fixed-fee contract to advance a small-molecule compound (CRS0540) through investigational new drug filing and Phase I clinical studies. These contracts have ranged from $98,980 to over $23 million, primarily involving synthesis and testing of novel antibiotic chemical compounds. The contracts have been both small business set-aside and non-set-aside, demonstrating the company's versatility in federal contracting. The work has consistently centered on researching and developing treatments for antibiotic-resistant infections, with a particular focus on creating innovative therapeutic approaches.
In the realm of federal grant awards, Crestone, Inc. has received funding from the National Institute of Allergy and Infectious Diseases to support cutting-edge medical research. A notable grant (R43AI179346) focuses on developing a novel small molecule therapeutic for acute Graft-versus-Host Disease (GVHD), specifically targeting the prevention and treatment of complications associated with allogeneic hematopoietic cell transplantation. The grant research explores the potential of their compound CRS3123 to selectively suppress pathogenic enterococci in the gut microbiome, which could potentially reduce GVHD occurrence without disrupting beneficial gut bacteria. This grant award, valued at an undisclosed amount, demonstrates the company's commitment to innovative medical research that addresses complex medical challenges through targeted microbiological interventions.
Quick answers
What is Crestone, Inc.'s UEI?
Crestone, Inc.'s Unique Entity ID (UEI) in SAM.gov is EDSLAP2J1BL8.
What is Crestone, Inc.'s CAGE code?
Crestone, Inc.'s CAGE code is 5RDJ6.
What is Crestone, Inc.'s primary NAICS code?
Crestone, Inc.'s primary NAICS code is 541715 (Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)).
Where is Crestone, Inc. located?
Crestone, Inc.'s physical address in SAM.gov is 6075 Longbow Dr #130, Boulder, CO 80301, USA.
Is Crestone, Inc. registered in SAM.gov?
Yes. Crestone, Inc.'s SAM.gov registration is active through May 1, 2027.
What is Crestone, Inc.'s most recent federal award?
Crestone, Inc.'s most recent federal contract award is Synthesis and testing laboratory services for research (36C25924P1167), from Veterans Integrated Service Network 19, on September 1, 2024.
On GovTribe
See Crestone, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors